Abuhasanein Suleiman, Chaves Vanessa, Mohsen Ali Moustafa, Al-Haddad Jasmine, Sunila Merete, Ströck Viveka, Jerlström Tomas, Liedberg Fredrik, Swärd Jesper, Gårdmark Truls, Jahnson Staffan, Kjölhede Henrik
Department of Urology, Institute of Clinical Science, Sahlgrenska Academy University of Gothenburg Göteborg Sweden.
Department of Surgery, Urology Section NU Hospital Group Uddevalla Sweden.
BJUI Compass. 2023 Oct 6;5(2):253-260. doi: 10.1002/bco2.300. eCollection 2024 Mar.
To perform a descriptive analysis of a series of patients with recurrent macroscopic haematuria after a primary standard evaluation including computed tomography urography (CTU) and cystoscopy negative for urinary bladder cancer (UBC) and upper tract urothelial cancer (UTUC) and to identify potential factors associated with occurrence of recurrent macroscopic haematuria.
All patients older than 50 years who underwent urological investigation for macroscopic haematuria with both cystoscopy and CTU 2015-2017 were retrospectively reviewed. A descriptive analysis of the primary and later investigations for recurrent macroscopic haematuria was performed. To investigate the association between explanatory variables and the occurrence of recurrent macroscopic haematuria, a Poisson regression analysis was performed.
A total of 1395 eligible individuals with primary standard investigation negative for UBC and UTUC were included. During a median follow-up of 6.2 (IQR 5.3-7) years, 248 (18%) patients had recurrent macroscopic haematuria, of whom six patients were diagnosed with UBC, two with prostate cancer, one with renal cell carcinoma and one had a suspected UTUC at the repeated investigation. Within 3 years, 148 patients (11%) experienced recurrent macroscopic haematuria, of whom two patients were diagnosed with low-grade UBC (TaG1-2), one with T2G3 UBC and one with low-risk prostate cancer. The presence of an indwelling catheter, use of antithrombotic medication, pathological findings at CTU or cystoscopy or history of pelvic radiotherapy were all statistically significant independent predictors for increased risk for recurrent macroscopic haematuria.
In the case of recurrent macroscopic haematuria within 3 years of primary standard evaluation for urinary tract cancer, there was a low risk of later urological malignancies in patients initially negative for UBC and UTUC. Therefore, waiting 3 years before conducting another complete investigation in cases of recurrent macroscopic haematuria might be appropriate.
对一系列在包括计算机断层扫描尿路造影(CTU)和膀胱镜检查在内的原发性标准评估后出现复发性肉眼血尿且膀胱癌(UBC)和上尿路尿路上皮癌(UTUC)检查结果为阴性的患者进行描述性分析,并确定与复发性肉眼血尿发生相关的潜在因素。
回顾性分析2015 - 2017年所有年龄大于50岁因肉眼血尿接受膀胱镜检查和CTU泌尿外科检查的患者。对复发性肉眼血尿的初次及后续检查进行描述性分析。为研究解释变量与复发性肉眼血尿发生之间的关联,进行了泊松回归分析。
共纳入1395例UBC和UTUC原发性标准检查结果为阴性的符合条件个体。在中位随访6.2(四分位间距5.3 - 7)年期间,248例(18%)患者出现复发性肉眼血尿,其中6例患者在重复检查时被诊断为UBC,2例为前列腺癌,1例为肾细胞癌,1例疑似UTUC。3年内,148例(11%)患者出现复发性肉眼血尿,其中2例被诊断为低级别UBC(TaG1 - 2),1例为T2G3 UBC,1例为低风险前列腺癌。留置导尿管、使用抗血栓药物、CTU或膀胱镜检查的病理结果或盆腔放疗史均为复发性肉眼血尿风险增加的统计学显著独立预测因素。
在尿路癌原发性标准评估后3年内出现复发性肉眼血尿的情况下,最初UBC和UTUC检查结果为阴性的患者后期发生泌尿系统恶性肿瘤的风险较低。因此,对于复发性肉眼血尿病例,在3年后再进行另一次全面检查可能是合适的。